Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2007

01.10.2007 | Gastrointestinal Oncology

A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer

verfasst von: Tristan D. Yan, BSc (Med) MBBS, Deborah Black, BSc DipEd MStat PhD, Paul H. Sugarbaker, MD, Jacqui Zhu, BSc (Med), Yutaka Yonemura, MD, PhD, George Petrou, BSc (Med) MBBS, David L. Morris, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer.

Methods

Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. After independent quality assessment and data extraction, data were pooled for meta-analysis.

Results

Thirteen reports of randomized controlled trials (RCTs) were included for quality appraisal and data extraction. Ten reports were judged to be of fair quality and subjected to meta-analysis. A significant improvement in survival was associated with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) alone (hazard ratio [HR] = 0.60; 95% CI = 0.43 to 0.83; p = 0.002) or HIIC combined with early postoperative intraperitoneal chemotherapy (EPIC) (HR = 0.45; 95% CI = 0.29 to 0.68; p = 0.0002). There was a trend towards survival improvement with normothermic intraoperative intraperitoneal chemotherapy (p = 0.06), but this was not significant with either EPIC alone or delayed postoperative intraperitoneal chemotherapy. Intraperitoneal chemotherapy was also found to be associated with higher risks of intra-abdominal abscess (RR = 2.37; 95% CI = 1.32 to 4.26; p = 0.003) and neutropenia (RR = 4.33; 95% CI = 1.49 to 12.61; p = 0.007).

Conclusions

The present meta-analysis indicates that HIIC with or without EPIC after resection of advanced gastric primary cancer is associated with improved overall survival. However, increased risk of intra-abdominal abscess and neutropenia are also demonstrated.
Literatur
1.
Zurück zum Zitat Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9PubMedCrossRef Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9PubMedCrossRef
2.
3.
4.
Zurück zum Zitat Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006;24:2188–96PubMedCrossRef Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006;24:2188–96PubMedCrossRef
5.
Zurück zum Zitat NHS Centre for Reviews and Dissemination. Undertaking Systemic Reviews of Research on Effectiveness: CRD’s Guidance for those Carrying Out or Commissioning Reviews. CRD Report 4 (2nd edn). York: NHS Centre for Reviews and Dissemination; 2001 NHS Centre for Reviews and Dissemination. Undertaking Systemic Reviews of Research on Effectiveness: CRD’s Guidance for those Carrying Out or Commissioning Reviews. CRD Report 4 (2nd edn). York: NHS Centre for Reviews and Dissemination; 2001
6.
Zurück zum Zitat Dixon E, Hameed M, Sutherland F, et al. Evaluating meta-analyses in the general surgical literature: a critical appraisal. Ann Surg 2005;241:450–9PubMedCrossRef Dixon E, Hameed M, Sutherland F, et al. Evaluating meta-analyses in the general surgical literature: a critical appraisal. Ann Surg 2005;241:450–9PubMedCrossRef
7.
Zurück zum Zitat Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34PubMedCrossRef Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34PubMedCrossRef
8.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188PubMedCrossRef
9.
Zurück zum Zitat Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34PubMed Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34PubMed
10.
Zurück zum Zitat Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58PubMedCrossRef Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58PubMedCrossRef
11.
Zurück zum Zitat Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer - final results of a randomised controlled study. Cancer 1994;73:2048–52PubMedCrossRef Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer - final results of a randomised controlled study. Cancer 1994;73:2048–52PubMedCrossRef
12.
Zurück zum Zitat Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529–34PubMedCrossRef Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529–34PubMedCrossRef
13.
Zurück zum Zitat Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterol 2001;48:1776–82 Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterol 2001;48:1776–82
14.
Zurück zum Zitat Zhang W, Su D, Wang K, et al. Clinical study in prophylactic use of intraperitoneal hyperthermic chemoperfusion for the prevention of peritoneal metastasis in patients with advanced gastric carcinoma. Shanxi Yiyao Zazhi 1998;27:67–9 Zhang W, Su D, Wang K, et al. Clinical study in prophylactic use of intraperitoneal hyperthermic chemoperfusion for the prevention of peritoneal metastasis in patients with advanced gastric carcinoma. Shanxi Yiyao Zazhi 1998;27:67–9
15.
Zurück zum Zitat Takahashi T, Hagiwara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg 1995;19:565–9PubMedCrossRef Takahashi T, Hagiwara A, Shimotsuma M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg 1995;19:565–9PubMedCrossRef
16.
Zurück zum Zitat Shimoyama S, Shimizu N, Kaminishi M. Type-oriented intraoperative and adjuvant chemotherapy and survival after curative resection of advanced gastric cancer. World J Surg 1999;23:284–91PubMedCrossRef Shimoyama S, Shimizu N, Kaminishi M. Type-oriented intraoperative and adjuvant chemotherapy and survival after curative resection of advanced gastric cancer. World J Surg 1999;23:284–91PubMedCrossRef
17.
Zurück zum Zitat Miyashiro I, Furukawa H, Sasako M, et al. No survival benefit with adjuvant chemotherapy for serosal-positive gastric cancer: Randomised trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer - Japan Clinical Oncology Group 9206-2. Proc ASCO-GI 84 (abstr 4), 2005 Miyashiro I, Furukawa H, Sasako M, et al. No survival benefit with adjuvant chemotherapy for serosal-positive gastric cancer: Randomised trial of adjuvant chemotherapy with cisplatin followed by oral fluorouracil in serosa-positive gastric cancer - Japan Clinical Oncology Group 9206-2. Proc ASCO-GI 84 (abstr 4), 2005
18.
Zurück zum Zitat Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomised multi-center trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998;16:2733–8PubMed Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomised multi-center trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998;16:2733–8PubMed
19.
Zurück zum Zitat Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomised trial. World J Surg 2001;25:985–90PubMedCrossRef Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomised trial. World J Surg 2001;25:985–90PubMedCrossRef
20.
Zurück zum Zitat Wei G, Fang GE, Bi JW, et al. Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai Zheng 2005;24:478–82PubMed Wei G, Fang GE, Bi JW, et al. Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai Zheng 2005;24:478–82PubMed
21.
Zurück zum Zitat Gao Z, Jiang Z, Zhou F. Clinical surgery of early intraperitoneal hyperthermic chemoperfusion for gastric cancer patients after operation. Zhonggou Zhongliu Linchuang 2002;29:294–5 Gao Z, Jiang Z, Zhou F. Clinical surgery of early intraperitoneal hyperthermic chemoperfusion for gastric cancer patients after operation. Zhonggou Zhongliu Linchuang 2002;29:294–5
22.
Zurück zum Zitat Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970–4PubMed Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970–4PubMed
23.
Zurück zum Zitat Zuo Y, Xu M, Shen D, et al. Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua Zhongliu Zazhi 2004;26:247–9PubMed Zuo Y, Xu M, Shen D, et al. Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua Zhongliu Zazhi 2004;26:247–9PubMed
24.
Zurück zum Zitat Tan C, Wang X, Xu Y, et al. Study for prevention of peritoneal dissemination of advanced gastric cancer by intraperitoneal thermochemotherapy. Shiyong Zhongliu Zazhi 2000;15:165–7 Tan C, Wang X, Xu Y, et al. Study for prevention of peritoneal dissemination of advanced gastric cancer by intraperitoneal thermochemotherapy. Shiyong Zhongliu Zazhi 2000;15:165–7
25.
Zurück zum Zitat Ikeguchi M, Kondou A, Oka A, et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995;161:581–6PubMed Ikeguchi M, Kondou A, Oka A, et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995;161:581–6PubMed
26.
Zurück zum Zitat Kaibara N, Hamazoe R, Iitsuka Y, et al. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterol 1989;36:75–8 Kaibara N, Hamazoe R, Iitsuka Y, et al. Hyperthermic peritoneal perfusion combined with anticancer chemotherapy as prophylactic treatment of peritoneal recurrence of gastric cancer. Hepatogastroenterol 1989;36:75–8
27.
Zurück zum Zitat Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232–7PubMedCrossRef Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232–7PubMedCrossRef
28.
Zurück zum Zitat Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomised controlled study. World J Surg 1994;18:150–5PubMedCrossRef Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomised controlled study. World J Surg 1994;18:150–5PubMedCrossRef
29.
Zurück zum Zitat Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629–1PubMedCrossRef Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629–1PubMedCrossRef
30.
Zurück zum Zitat Takahashi T, Hagiwara A, Shimotsuma M. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles for patients with advanced gastric cancer. Eur J Surg Oncol 1994;20:183–4PubMed Takahashi T, Hagiwara A, Shimotsuma M. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles for patients with advanced gastric cancer. Eur J Surg Oncol 1994;20:183–4PubMed
31.
Zurück zum Zitat Yu W, Whang I, Averbach A, et al. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surg 1998;64:1104–8PubMed Yu W, Whang I, Averbach A, et al. Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surg 1998;64:1104–8PubMed
32.
Zurück zum Zitat Yu W, Whang I, Suh I, et al. Prospective randomised trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347–54PubMedCrossRef Yu W, Whang I, Suh I, et al. Prospective randomised trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347–54PubMedCrossRef
33.
Zurück zum Zitat Yu W, Sugarbaker P, Whang I. Randomised controlled trial of early postoperative intraperitoneal chemotherapy in gastric cancer: a preliminary report. Reg Cancer Treat 1994;2:90–3 Yu W, Sugarbaker P, Whang I. Randomised controlled trial of early postoperative intraperitoneal chemotherapy in gastric cancer: a preliminary report. Reg Cancer Treat 1994;2:90–3
34.
Zurück zum Zitat Schiessel R, Funovics J, Schick B, et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomised trial. Acta Med Austriaca 1989;16:68–9PubMed Schiessel R, Funovics J, Schick B, et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomised trial. Acta Med Austriaca 1989;16:68–9PubMed
35.
Zurück zum Zitat Xu DZ, Zhan YQ, Sun XW, et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004;10:2727–30PubMed Xu DZ, Zhan YQ, Sun XW, et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004;10:2727–30PubMed
36.
Zurück zum Zitat Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955;159:1704–7 Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955;159:1704–7
37.
Zurück zum Zitat Jones RB, Myers CE, Guarino AM, et al. High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol 1978;1:161–6PubMedCrossRef Jones RB, Myers CE, Guarino AM, et al. High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol 1978;1:161–6PubMedCrossRef
38.
Zurück zum Zitat Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev CD005340, 2006 Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev CD005340, 2006
39.
Zurück zum Zitat Verwaal VJ, van Ruth S, de Bree E, et al. Randomised trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43PubMedCrossRef Verwaal VJ, van Ruth S, de Bree E, et al. Randomised trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43PubMedCrossRef
40.
Zurück zum Zitat Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76PubMedCrossRef Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76PubMedCrossRef
41.
Zurück zum Zitat Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol doi:10.1245/s10434-006-9182-x, 2006 Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol doi:10.1245/s10434-006-9182-x, 2006
42.
Zurück zum Zitat Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol doi:10.1093/annonc/mdl428, 2006 Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol doi:10.1093/annonc/mdl428, 2006
43.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20PubMedCrossRef Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20PubMedCrossRef
44.
Zurück zum Zitat MacDonald JS, Malley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–9PubMedCrossRef MacDonald JS, Malley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–9PubMedCrossRef
45.
Zurück zum Zitat Cascinu S, Labianca R, Barone C, et al Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin and Epidoxorubibin in a randomized controlled trial. J Natl Cancer Inst doi: 10.1093/jnci/djk131, 2007 Cascinu S, Labianca R, Barone C, et al Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin and Epidoxorubibin in a randomized controlled trial. J Natl Cancer Inst doi: 10.1093/jnci/djk131, 2007
46.
Zurück zum Zitat Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32PubMedCrossRef Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32PubMedCrossRef
47.
Zurück zum Zitat Los G, Mutsaers PH, Lenglet WJ, et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389–94PubMedCrossRef Los G, Mutsaers PH, Lenglet WJ, et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389–94PubMedCrossRef
48.
Zurück zum Zitat Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370–5PubMedCrossRef Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370–5PubMedCrossRef
49.
Zurück zum Zitat Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–6PubMedCrossRef Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg 2004;139:20–6PubMedCrossRef
50.
Zurück zum Zitat Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–63PubMedCrossRef Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454–63PubMedCrossRef
51.
Zurück zum Zitat Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:77–9CrossRef Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:77–9CrossRef
Metadaten
Titel
A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer
verfasst von
Tristan D. Yan, BSc (Med) MBBS
Deborah Black, BSc DipEd MStat PhD
Paul H. Sugarbaker, MD
Jacqui Zhu, BSc (Med)
Yutaka Yonemura, MD, PhD
George Petrou, BSc (Med) MBBS
David L. Morris, MD, PhD
Publikationsdatum
01.10.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9487-4

Weitere Artikel der Ausgabe 10/2007

Annals of Surgical Oncology 10/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.